Faster Clinical Trials Test Pharma’s Supply Chains
2 September 2026.
Faster trials increase demand for flexible, resilient clinical supply networks
Newsletter
Can Australian Industry Deliver an A$425bn Defence Expansion?
28 August 2026.
Australia’s defence build-up tests industry, supply chains and delivery capacity
US Pharma’s Manufacturing Boom: Who Wins?
26 August 2026.
US pharma investment shifts toward strategic, complex, domestic manufacturing capacity
Washington’s $22.9bn Tomahawk Push Tests US Missile Production
21 August 2026.
Washington expands missile production, but rebuilding depleted inventories takes years
Why Batteries, Bauxite and Magnets Are Becoming Defence Priorities
14 August 2026.
Washington targets critical material dependencies across batteries, bauxite and magnets
Can Moderna Make mRNA Work in Flu?
12 August 2026.
Moderna’s flu approval tests whether mRNA can deliver commercial scale
Washington Targets Missile and Drone Weak Links
7 August 2026.
Washington targets missile and drone bottlenecks across critical defence supply chains
Biologic Success Starts with Drug Delivery
5 August 2026.
Drug delivery is reshaping biologics development, manufacturing, access and competition
US Missile-Defence Deals Reach Deeper into the Supply Chain
31 July 2026.
Washington targets missile-supply bottlenecks to expand PAC-3 and THAAD production
Ageing Rewrites Pharma Portfolio Strategy
29 July 2026.
Ageing reshapes pharma portfolios as access, evidence and delivery determine growth
UK Raises Its Combat Air Ambitions as Canada Joins GCAP
24 July 2026.
Canada joins GCAP as Britain accelerates its next-generation combat-air strategy
When Vaccine Policy Becomes Market Risk
22 July 2026.
Policy, platforms and manufacturing are reshaping global vaccine market opportunities
US Defence: Faster, Lower-Cost Production
17 July 2026.
US reforms target faster production, secure supply chains, lower costs
Cell & Gene Therapy Manufacturing: The Race to Scale
15 July 2026.
Manufacturing readiness now determines which cell and gene therapies scale
GCAP’s £4.6bn: Contract Tests Military Aviation
10 July 2026.
GCAP contract tests allied ambition, industrial capacity and combat-air delivery
UK’s £5bn Drone Plan Tests Defence Delivery
3 July 2026.
UK drone investment tests hybrid force design, funding and delivery
Healthcare Moves Home. Pharma Follows
1 July 2026.
Healthcare moves home as pharma’s commercial model shifts toward patients
The Next Pharma Challenge: Treatment Persistence
24 June 2026.
Patient persistence is becoming pharma’s next growth test after launch
Winning the Drone Age Is Now an Industrial Challenge
19 June 2026.
Low-cost drones force faster procurement and resilient defence supply chains
The Business of Prevention: Why Pharma Is Moving Upstream
17 June 2026.
Prevention-led pharma growth depends on earlier intervention, access and scale
